Myriad Genetics, Inc. (MYGN)
3.98
-0.37
(-8.51%)
USD |
NASDAQ |
Oct 16, 16:00
3.975
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics Research and Development Expense (Annual) : 106.80M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 106.80M |
| December 31, 2024 | 113.40M |
| December 31, 2023 | 88.70M |
| December 31, 2022 | 85.40M |
| December 31, 2021 | 81.90M |
| June 30, 2020 | 77.20M |
| June 30, 2019 | 85.90M |
| June 30, 2018 | 70.80M |
| June 30, 2017 | 74.40M |
| June 30, 2016 | 70.60M |
| June 30, 2015 | 75.50M |
| June 30, 2014 | 67.48M |
| June 30, 2013 | 52.22M |
| June 30, 2012 | 42.64M |
| Date | Value |
|---|---|
| June 30, 2011 | 27.75M |
| June 30, 2010 | 21.87M |
| June 30, 2009 | 17.91M |
| June 30, 2008 | 18.48M |
| June 30, 2007 | 98.67M |
| June 30, 2006 | 83.76M |
| June 30, 2005 | 59.24M |
| June 30, 2004 | 50.70M |
| June 30, 2003 | 47.59M |
| June 30, 2002 | 36.29M |
| June 30, 2001 | 33.82M |
| June 30, 2000 | 28.10M |
| June 30, 1999 | 23.45M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Natera, Inc. | 624.11M |
| Sera Prognostics, Inc. | 12.35M |
| BioRestorative Therapies, Inc. | 10.09M |
| CareDx, Inc. | 71.43M |
| Exagen, Inc. | 6.254M |